News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 03, 2016, 07:00 ET Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

 Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib),...


Jul 07, 2016, 16:40 ET Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma

Novartis today announced that the US Food and Drug Administration (FDA) has approved an expanded age range for Xolair® (omalizumab) to include...


Jun 29, 2016, 17:15 ET Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)

 Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall...


Jun 22, 2016, 11:35 ET Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

 A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all...


Jun 06, 2016, 14:40 ET Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

 Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive...


Jun 04, 2016, 16:05 ET Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

 Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna...


Jun 03, 2016, 08:00 ET Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS

 Novartis today announced data from a randomized, prospective, Phase IV, open-label study that demonstrated patient retention rate with...


Jun 02, 2016, 16:17 ET Novartis announces US collaboration to co-promote Lenvima® in combination with everolimus for advanced renal cell carcinoma (RCC)

Novartis Pharmaceuticals Corporation today announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs...


May 18, 2016, 17:09 ET Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical...


Feb 26, 2016, 15:43 ET FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)

Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment...


Feb 19, 2016, 07:15 ET Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

 Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PKC412...


Jan 26, 2016, 09:47 ET Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for two new indications -...


Jan 25, 2016, 16:30 ET Novartis teams up with Pro Football Hall of Famer Troy Aikman on advanced melanoma educational and community support program

 Pro Football Legend, Hall of Famer and former melanoma patient Troy Aikman is teaming up with Novartis and the advocacy community to educate...


Dec 23, 2015, 17:04 ET Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis

 Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing...


Dec 23, 2015, 17:04 ET Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis

 Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing...


Dec 07, 2015, 15:03 ET Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL

The latest findings from an ongoing Phase II study of CTL019, an investigational chimeric antigen receptor T cell (CART) therapy, further support...


Dec 07, 2015, 15:03 ET Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL

The latest findings from an ongoing Phase II study of CTL019, an investigational chimeric antigen receptor T cell (CART) therapy, further support...


Dec 06, 2015, 11:15 ET Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

 Novartis today announced positive results from the global Phase III RATIFY (CALGB 10603) clinical trial. In the study, adult patients under 60...


Dec 06, 2015, 11:15 ET Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

 Novartis today announced positive results from the global Phase III RATIFY (CALGB 10603) clinical trial. In the study, adult patients under 60...


Dec 06, 2015, 07:46 ET Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma

 Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART)...


Dec 06, 2015, 07:46 ET Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma

 Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART)...


Nov 30, 2015, 07:15 ET Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research

 Novartis will demonstrate the strength of its research program and portfolio at the 57th American Society of Hematology (ASH) Annual Meeting....


Nov 20, 2015, 17:14 ET Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data

Novartis today announced that the US Food and Drug Administration (FDA) has granted regular approval for the combination of Tafinlar®...


Nov 10, 2015, 17:30 ET Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows

 Novartis announced today data from a new analysis demonstrating that fewer heart failure patients with reduced ejection fraction (HFrEF)...